Because fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all age groups, patients receiving ofloxacin should be informed of this potential adverse effect and the drug should be discontinued if pain, swelling, inflammation, or rupture of a tendon occurs.
Ofloxacin may cause CNS stimulation that potentially could result in tremor, restlessness, lightheadedness, mental confusion, hallucinations, and/or seizures, the drug should be used with caution in patients with known or suspected CNS disorders that predispose to seizures or lower the seizure threshold.
Use of ofloxacin should be avoided in patients with a history of QT interval prolongation, in those with uncorrected electrolyte disorders (e.g., hypokalemia) and in those receiving class IA or class III antiarrhythmic agents.
Patients receiving ofloxacin should be cautioned to avoid excessive exposure to direct sunlight or artificial ultraviolet light and to discontinue therapy if phototoxicity occurs.
Ofloxacin should be used with caution in patients with impaired renal or hepatic function since elimination of the drug may be reduced in these patients.